Navigation Links
Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
Date:9/18/2007

tements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007 and quarterly report on form 10-Q for the period ended June 30, 2007.

References

1. Joos GF, Schelfhout VJ, Kanniess F et al. Bronchodilator effects of

aclidinium bromide, a novel long-acting anticholinergic, in COPD

patients: a phase II study. European Respiratory Society (ERS) Annual

Congress, September 2007. Poster.

2. Schelfhout VJ, Joos GF, Gil EG et al. Bronchodilator/bronchoprotective

effects of aclidinium bromide, a novel long-acting anticholinergic: a

phase I study. European Respiratory Society (ERS) Annual Congress,

September 2007. Poster.

3. Gavalda A, Miralpeix M, Ramos I et al. Aclidinium bromide, a novel

muscarinic receptor antagonist combining long residence at M3 receptors

and rapid plasma clearance. European Respiratory Society (ERS) Annual

Congress, September 2007. Poster.

4. Miralpeix M, Gavalda A, Morcillo E et al. Assessment of the potency and

duration of action of aclidinium bromide in guinea pig isolated trachea

in vitro. European Respiratory Society (ERS) Annual Congress, September

2007. Poster.

5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy

for the diagnosis, management, and prevention of chronic obstructive

pulmonary disease; MCR Vision, Inc.; 2006

6. CDC, http://www.cdc.gov/nceh/airpollution/copd/copdfaq.htm, accessed

Sept
'/>"/>

SOURCE Forest Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) ... focus on Omega-3 therapies for cardiovascular disease (CVD) ... financial results for the fiscal year ended December ... in Canadian dollars unless otherwise stated. ... the right strategic partners and additional capitalization in ...
(Date:4/30/2015)... , April 30, 2015  Accuray Incorporated ... has signed an agreement with MIM Software Inc. ... TomoTherapy ® and CyberKnife ® product portfolios. ... and MIM technology. This is Accuray,s second collaboration ... development of the first iPad-based treatment plan review ...
(Date:4/30/2015)... , April 30, 2015  Thoratec Corporation (NASDAQ: ... support therapies to save, support and restore failing hearts, ... America Merrill Lynch 2015 Healthcare Conference on Thursday, May ... and Chief Executive Officer, will provide an update on ... (1:40 p.m., Eastern Daylight Time). The presentation ...
Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2
... WELLINGTON , Fla., May 10 Dr. ... children with newly diagnosed type 1 diabetes for Protege Encore, ... second of two Phase III studies testing the safety and ... known as Protege, has completed enrollment of more than 530 ...
... Ireland , May 10 Warner Chilcott plc ... of America Merrill Lynch Healthcare Conference on Tuesday, May 11, 2010 ... be Paul Herendeen , Executive Vice President and Chief Financial Officer. , ... Warner Chilcott ,s presentation will be ...
Cached Medicine Technology:Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes 2
(Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part of ... technology products available to consumers. Scott Steinberg, a technology expert ... with viewers how to protect their private information. , A ... and even more so online. It helps everyone stay connected ... world. In terms of work, the internet makes things more ...
(Date:5/3/2015)... Mateo, CA (PRWEB) May 03, 2015 ... service, MnemeTherapy® at two upcoming area seminars. The first ... the PSA Annual Regional Stroke Conference to be held ... be offered on Wednesday, May 13 during the Dementia ... Plaza. , “These seminars offer an excellent opportunity ...
(Date:5/3/2015)... It is not too late to register to take ... of Lissa Anne Been in Arnold, Missouri on May 9, ... to honor her loving memory. It has benefited the renowned Brain ... turned 37, Lissa suffered a brain aneurysm . After two ... This event is designed to serve as a remembrance of her ...
(Date:5/2/2015)... As one of only 30 Illinois companies to ... Achievement and Recognition Program (SHARP) certification, Essentra Specialty ... Illinois Department of Labor to host this special event. ... by the Occupational Safety and Health Administration’s (“OSHA”) Onsite ... meet or exceed all of the necessary regulations and ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 Vancouver fencing company, ... now provide valuable advice to prospective clients related to their ... looking to install railings around their decks and patios. While ... questions that pop up once the person rolls up their ... of installing a railing in finding a gate that matches ...
Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2
... & Full Year 2008 Earnings Conference Call , Thursday, February 12, ... Jan. 12 Cephalon, Inc . (Nasdaq: CEPH ... quarter and full year 2008 results for 5:00 p.m. EST on ... 4:10 p.m. EST Q4 & FY 2008 ...
... a sagging economy? Not necessarily the quick fix that you ... plastic surgeons.Recently, the U.S. Food and Drug Administration (FDA) gathered ... the use of dermal fillers. Although the injections have been ... (the creases running from the nose to the corners of ...
... Beginning Thursday, January 15, 2009, cosmetic surgeons from around ... Cosmetic Surgery,s 25th Anniversary Scientific Meeting to share and ... A Day Over Twenty-five" will be held from January ... Ridge Resort and Spa in Phoenix, Arizona.AACS continues its ...
... to study inherited susceptibility for skin cancer in mice. In the process, ... role in controlling this susceptibility. The technique, the scientists say, could ... ... January 12, 2009 -- UCSF researchers have used a new ...
... Steve Shulman to BoardHOUSTON, Jan. 12 Access ... of outsourced medical implantable device management solutions to ... board of directors has appointed board member Steve ... appointment following its second consecutive year of revenue ...
... of minimally invasive surgery procedures in operating theatres. However, ... much to be desired. Researcher Magdalena Chmarra has changed ... system which records and analyses the surgeon,s movements. As ... an objective benchmark for measuring a surgeon,s basic skills ...
Cached Medicine News:Health News:Dr. Sherrell Aston Addresses the Popularity of Dermal Fillers and Possible Long Term Side Effects 2Health News:The State of the Cosmetic Surgery Industry is Discussed at AACS 25th Anniversary Scientific Meeting 2Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 2Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 3Health News:UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes 4Health News:Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board 2Health News:Access MediQuip Appoints Former Priority Healthcare CEO to Chairman of the Board 3Health News:New training method helps surgeons evaluate their own minimally invasive surgery skills 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: